PNPLA3 and metabolic dysfunction-associated steatohepatitis: A dose-responsive, 50% decrease in hepatic Pnpla3 mRNA levels was achieved without signs of toxicity, a reduction that is predicted to have a measurable clinical benefit in NASH patients (Figure 3).